Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

[5] Pinke KH, et al. Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy? Neurotherapeutics. 2020 Jan;17(1):218-234. [6] Brown MA, Weinberg RB. Mast Cells and ...

The U.S. Food and Drug Administration on Thursday approved Roche's under-the-skin injection to treat patients with multiple ...

Rutgers Health researchers will enroll primary or secondary progressive multiple sclerosis (p-MS) patients to see if an ...

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...

New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...

Rich nations hold millions of mpox vaccines as Africa grapples with an outbreak, while the US FDA approves Roche's multiple ...

The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...

A pharmaceutical and a nonprofit are teaming up to evaluate segesterone acetate as a possible MS therapy to restore lost myelin in patients.

New research highlights the benefits of starting monoclonal antibody therapy for multiple sclerosis in childhood. The study, ...

The National Multiple Sclerosis Society (USA) has awarded a grant of 1 million dollars to Dr. Isabel Pérez-Otaño, who leads the Plasticity and Remodeling of Neural Circuits laboratory at the Institute ...